VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

AACR 2022 | RTX-240: allogeneic RBCs drive expansion & trafficking of CD8+ T-cells & NK cells into the TME

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from a Phase I study evaluating RTX-240, an allogeneic cellular therapy genetically engineered to express high copy numbers of trimeric 4-1BBL and IL-15/IL-15Rα fusion proteins on the red blood cell (RBC) surface membrane in order to activate and expand CD8+ memory T-cells and NK cells. RTX-240 is well tolerated at all tested doses and leads to activation, expansion, and trafficking of memory CD8+ T cells and NK cells into the tumor microenvironment (TME). This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter